Amikacin Sulfate Injection

Specification: 2ml: 0.2g
Packaging: 10 ampoules/box

Indications of Amikacin Sulfate Injection:
Amikacin Sulfate injection is indicated in the treatment of serious infections caused by Staphylococcus (methicillin-susceptible strains) or due to susceptible strains of gram-negative bacteria, including Pseudomonas aeruginosa and some other pseudomonas species, Escherichia coli, Proteus, Klebsiella-Enterobacter-Serratia species, and Acinetobacter species.

That is to say, Amikacin Sulfate injection is suitable for the treatment of serious infections like bacteremia or septicemia, bacterial endocarditis, lower respiratory tract infections, bone and joints infections, biliary tract infections, intra-abdominal infections, complicated urinary tract infections, skin and soft tissue infections, etc.

In addition, as a result of its stability against aminoglycosides-modifying enzymes, Amikacin Sulfate injection is especially suitable for the treatment of serious infections caused by kanamycin, gentamycin and/or tobramycin-resistant strains of gram negative bacilli.

Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratiaspecies, and Acinetobacter (Mima-Herellea) species.
Amikacin Sulfate Injection is effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Amikacin is also effective in serious complicated and recurrent urinary tract infections due to these organisms.
Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococcal/Gram-negative infections.